Clicks133
Rafał_Ovile

POTENCJALNY KONFLIKT INTERESÓW U DORADCÓW MEDYCZNYCH RZĄDU RP

POTENCJALNY KONFLIKT INTERESÓW U DORADCÓW MEDYCZNYCH RZĄDU RP

Zarząd Główny Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych
Prof. dr hab. Robert Flisiak – prezes – konsultacje i fundusze na badania od AbbVie, Gilead, Merck i Roche.
Prof. dr hab. Małgorzata Pawłowska – wiceprezes – konsultacje od AbbVie, Gilead, Merck, and Roche oraz fundusze na badania od AbbVie, Gilead, and Roche
Prof. dr hab. Krzysztof Tomasiewicz – wiceprezes – konsultacje od AbbVie, Alfa Wasserman, BMS, Gilead, Janssen, Merck, and Roche oraz fundusze na badania od AbbVie, BMS, Gilead, Janssen, Merck, and Roche.
Prof. dr hab. Michał Garlicki – konsultacje od AbbVie, Bristol‐Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Roche, Sanofi Pasteur oraz fundusze na badania od Amgen, Janssen, and Pfizer.
Prof. dr hab. Waldemar Halota – wykłady sponsorowane od Roche, Janssen, MSD, AbbVie and Gilead; konsultacje od AbbVie, BMS, Gilead, Janssen, Merck, Roche oraz fundusze na badania od AbbVie, Gilead, and Roche
Prof. dr hab. Anna Piekarska – konsultacje od AbbVie, Gilead, Merck i Roche.
Prof. dr hab. Krzysztof Simon – konsulatacje i wykłady sponsorowane od AbbVie, Gilead i Merck, konsultacje od.Alfa‐Wassermann, Novartis, Lilly, and Bayer oraz fundusze na badania od AbbVie, Allergan, Bayer, EISAI, Gilead, Intercept, and Pfizer.
Dr hab. Jerzy Jaroszewicz – konsultacje od AbbVie, Gilead, and Roche and jest rzecznikiem dla AbbVie, Alfasigma, MSD, Gilead i PRO.MED. CS
Dr hab. Dorota Zarębska-Michaluk – konsultacje i wykłady sponsorowane od received consultancy od AbbVie, Gilead, and Merck.
Dr hab. Dorota Kozielewicz – wykłady sponsorowane od from Roche i Janssen.
Dr med. Agnieszka Czauż-Andrzejuk – fundusze na badania od AbbVie and Merck.
Dr med. Alicja Kalinowska otrzymała granty od Novartis i wykłady sponsorowane i konsultacje od Biogen, Bayer, Novartis, Roche, Merck, Teva, CSL Behring, Shire, and Sanofi-Genzyme.
Źródła:
(1) onlinelibrary.wiley.com/action/cookieAbsent
(2) misuse.ncbi.nlm.nih.gov/…zHX_cirmcTWhAm02cVnaWg67wioV3c
(3) pdfs.semanticscholar.org/…caf83b0e3756afdb27e8e71613.pdf
(1) Declaration of conflict of interest: Dorota Zarębska‐Michaluk and Krzysztof Simon received consultancy and sponsored lectures from AbbVie, Gilead, and Merck. Jerzy Jaroszewicz received consultancy from AbbVie, Gilead, and Roche and is a speaker for AbbVie, Alfasigma, MSD, Gilead, and PRO.MED. CS. Krzysztof Simon received consultancy from AbbVie, Gilead, Merck, Alfa‐Wassermann, Novartis, Lilly, and Bayer and also acquired research funding from AbbVie, Allergan, Bayer, EISAI, Gilead, Intercept, and Pfizer. Krzysztof Tomasiewicz received consultancy from AbbVie, Alfa Wasserman, BMS, Gilead, Janssen, Merck, and Roche and research funding from AbbVie, BMS, Gilead, Janssen, Merck, and Roche. Aleksander Garlicki received consultancy from AbbVie, Bristol‐Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Roche, and Sanofi Pasteur and research funding from Amgen, Janssen, and Pfizer. Ewa Janczewska received consultancy from AbbVie, Gilead and research funding from AbbVie, Allergan, Gilead, Janssen, Merck, and Roche. Dorota Dybowska received sponsored lecture from Roche. Waldemar Halota received consultancy from AbbVie, BMS, Gilead, Janssen, Merck, Roche and also acquired research funding from AbbVie, Gilead, and Roche. Małgorzata Pawłowska received consultancy from AbbVie, Gilead, Merck, and Roche and acquired research funding from AbbVie, Gilead, and Roche. Włodzimierz Mazur received consultancy from AbbVie, Gilead, Merck and research funding from AbbVie, Gilead, and Janssen. Agnieszka Czauż‐Andrzejuk received research funding from AbbVie and Merck. Hanna Berak received consultancy from Gilead and sponsored lectures from Abbvie, Gilead, and MSD. Łukasz Socha received consultancy from BMS. Jakub Klapaczyński received sponsored lectures from Gilead. Anna Piekarska received consultancy from AbbVie, Gilead, Merck, and Roche. Olga Tronina received consultancy from AbbVie. Robert Flisiak received consultancy and research funding from AbbVie, Gilead, Merck, and Roche. Teresa Belica‐Wdowik received consultancy from Gilead and research funding and consultancy from AbbVie. Olga Tronina received consultancy from AbbVie. Iwona Buczyńska, Beata Lorenc, Magdalena Tudrujek‐Zdunek, Marek Sitko, Paweł Pabjan, Andrzej Horban, Maria Blaszkowska, Beata Dobracka, Zbigniew Deroń, Jolanta Białkowska‐Warzecha, and Łukasz Laurans declare no conflict of interest.
(2) Conflict of interest: Dorota Kozielewicz has received a speaker honorarium from Roche and Janssen. Waldemar Halota has received a speaker honorarium from Roche, Janssen, MSD, AbbVie and Gilead. Magdalena Wietlicka-Piszcz has nothing to declare.
(3) Conflicts of interest: Alicja Kalinowska received grant funding from Novartis and received compensation for speaking and consulting services from Biogen, Bayer, Novartis, Roche, Merck, Teva, CSL Behring, Shire, and Sanofi-Genzyme; Alina Kułakowska received compensation for speaking and consulting services from Biogen, Bayer, Novartis, Roche, Merck, Teva, and Sanofi-Genzyme; Monika Adamczyk-Sowa received compensation for speaking and consulting services from Biogen, Bayer, Novartis, Roche, Merck, Teva and Sanofi-Genzyme; Bronislawa Pietrzak, Krzysztof Czajkowski and Piotr Radziszewski have no conflict of interest to declare; Katarzyna Kurowska received compensation for speaking and consulting services from Biogen, Bayer, Novartis, Roche, Merck, Teva, and Sanofi-Genzyme; Konrad Rejdak received compensation for speaking and consulting services from Biogen, Bayer, Novartis, Roche, Merck, Teva, and Sanofi-Genzyme; Halina Bartosik-Psujek received
compensation for speaking and consulting services from Biogen, Bayer, Novartis, Roche, Merck, Teva, CSL Behring, and Sanofi-Genzyme.